Founder & CEO

James Misselbrook, Ph.D. is the founder and CEO of GemBio, with deep expertise in building oligonucleotide manufacturing capabilities across the full development lifecycle, from RUO to GMP and commercial scale. He was an early team member at Curative, where he helped develop its first diagnostic product and scale operations from seed stage to national deployment, supporting tens of millions of tests and rapid organizational growth. James has led product development and team growth at Synthego and Agilent Technologies, launching novel RNA tools and production platforms. He holds a Ph.D. in Biochemistry from the University of Sussex, and Master’s and Bachelor’s degrees in Organic Chemistry from Loughborough University.

Fractional CTO

Lee Spraggon, Ph.D. is Director of the READY Center at UCSF’s QBI, where he leads iPSC engineering for disease modeling and functional genomics. Formerly Senior Director at Synthego, he launched the NIH iNDI initiative, engineering over 100 Alzheimer’s variants. He built large-scale editing platforms in Oxford and has led cross-functional teams across industry and academia. Lee holds a Ph.D. in Genetics from the University of Edinburgh and completed postdoctoral training at Columbia and Memorial Sloan Kettering in genomic engineering and RNA therapeutics.

Fractional CBO